ArticleAllergy2026
Chitin Is a Potent Inducer of Type 2 Airway Inflammation Independent of Endogenous Chitinolytic Activity.
Article in Allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Chitin is highly abundant in organisms with allergenic potential such as house dust mites, fungi, nematodes, and arthropods. Several observations suggest a role for chitin in allergic disease, although the mechanism of action is poorly understood. Humans and mice express highly conserved chitin-degrading chitinases: acidic mammalian chitinase (AMCase; encoded by CHIA in humans and Chia in mice) and chitotriosidase (Chit1; encoded by CHIT1 in humans and Chit1 in mice), which have been suggested to modulate allergic responses through enzymatic degradation of chitins. Humans with nasal polyposis and mice with type 2 immune responses had increased chitinolytic activity in their airways, emanating from two different enzymes. Due to redundancy between both enzymes and lack of a mouse model completely devoid of all chitinolytic activity, their precise role in regulating type 2 immunity to chitin remains controversial. Using transgenic mice with single or combined deficiency of Chia and Chit1, we investigated the impact of chitin and chitinases on type 2 immunity. Our data demonstrate that chitin is a potent adjuvant for type 2 inflammation by triggering increased activation and migration of type 2 dendritic cells, with consequent increased polarization of T helper 2 cells. This adjuvant potential of chitin is however unaffected by the absence of endogenous chitinolytic activity in different models of allergic airway disease. Taken together, we here highlight the role of chitin as an allergenic adjuvant and question if the strength of this response is influenced by endogenous chitinases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.